CA2236598C - Traitement de la cardiomyopathie par elimination des auto-anticorps - Google Patents

Traitement de la cardiomyopathie par elimination des auto-anticorps Download PDF

Info

Publication number
CA2236598C
CA2236598C CA002236598A CA2236598A CA2236598C CA 2236598 C CA2236598 C CA 2236598C CA 002236598 A CA002236598 A CA 002236598A CA 2236598 A CA2236598 A CA 2236598A CA 2236598 C CA2236598 C CA 2236598C
Authority
CA
Canada
Prior art keywords
plasma
column
specific ligand
antibodies
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002236598A
Other languages
English (en)
Other versions
CA2236598A1 (fr
Inventor
Stephan Felix
Petra Reinke
Stefan Brehme
Gert Baumann
Robert Koll
Jutta Muller-Derlich
Reiner Spaethe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edwards Lifesciences Corp
Original Assignee
Edwards Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edwards Lifesciences Corp filed Critical Edwards Lifesciences Corp
Priority claimed from PCT/US1996/018457 external-priority patent/WO1997017980A1/fr
Publication of CA2236598A1 publication Critical patent/CA2236598A1/fr
Application granted granted Critical
Publication of CA2236598C publication Critical patent/CA2236598C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Abstract

La présente invention concerne un traitement de la cardiomyopathie par immunoaphérèse. Ce traitement consiste à faire passer le plasma d'un patient par une colonne à laquelle est couplé un ligand spécifique de l'immunoglobuline humaine, éliminant ainsi du plasma du patient une partie importante de l'immunoglobuline, et à réperfuser le plasma au patient. La caractéristique de l'invention est d'utiliser un ligand spécifique de l'immunoglobuline humaine dans la fabrication d'une colonne à laquelle est couplé ce ligand, laquelle colonne convient particulièrement au traitement par immunoaphérèse d'un patient soufrant de cardiomyopathie. Ce ligand spécifique fixe, et de ce fait élimine les auto-anticorps humains qui sont nocifs pour le tissu cardiaque, ces anticorps étant ceux qui agissent contre les récepteurs alpha -adrénergiques, contre les vecteurs de l'adénosine-diphosphate et de l'adénosine-triphosphate, les chaînes lourdes de myosine alpha et beta et les translocateurs nucléotidiques d'adénine. Le traitement par immunoaphérèse utilisant cette colonne permet d'améliorer les paramètres hémodynamiques tels que la pression artérielle moyenne, la pression pulmonaire moyenne, la pression capillaire pulmonaire, la pression ventriculaire droite, le débit cardiaque, l'index cardiaque, le débit systolique et la résistance vasculaire systémique.
CA002236598A 1995-11-15 1996-11-15 Traitement de la cardiomyopathie par elimination des auto-anticorps Expired - Lifetime CA2236598C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55926295A 1995-11-15 1995-11-15
US08/559,262 1995-11-15
PCT/US1996/018457 WO1997017980A1 (fr) 1995-11-15 1996-11-15 Traitement de la cardiomyopathie par elimination des auto-anticorps

Publications (2)

Publication Number Publication Date
CA2236598A1 CA2236598A1 (fr) 1997-05-22
CA2236598C true CA2236598C (fr) 2006-09-12

Family

ID=36999314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002236598A Expired - Lifetime CA2236598C (fr) 1995-11-15 1996-11-15 Traitement de la cardiomyopathie par elimination des auto-anticorps

Country Status (1)

Country Link
CA (1) CA2236598C (fr)

Also Published As

Publication number Publication date
CA2236598A1 (fr) 1997-05-22

Similar Documents

Publication Publication Date Title
EP0862444B1 (fr) Traitement de la cardiomyopathie dilatee par elimination d' auto-anticorps
CN101420992B (zh) 用于体外处理含粒子的液体的可再生过滤器及其应用
JP6169495B2 (ja) 妊娠関連高血圧性障害を治療または予防するための方法およびシステム
Wallukat et al. The First Aptamer-Apheresis Column Specifically for Clearing Blood of β1-Receptor Autoantibodies–A Successful Proof of Principle Using Autoantibody-Positive SHR Rats–
US20110160636A1 (en) Device and method for inhibiting complement activation
Haupt et al. Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin
US6994970B1 (en) Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (DCM)
Ikonomov et al. Adsorption profile of commercially available adsorbents: an in vitro evaluation
Bosch Recent advances in therapeutic apheresis
CA2236598C (fr) Traitement de la cardiomyopathie par elimination des auto-anticorps
US6030614A (en) Ameliorating immunological rejection of allograft
Schimke et al. Reduced oxidative stress in parallel to improved cardiac performance one year after selective removal of anti‐beta 1‐adrenoreceptor autoantibodies in patients with idiopathic dilated cardiomyopathy: data of a preliminary study
Camino et al. Beta1-adrenergic receptor antibodies in children with dilated cardiomyopathy
JP2001509517A (ja) 微小循環障害の治療及び／又は予防のための薬剤
Gordon et al. Humoral immune response following extracorporeal immunoadsorption therapy of patients with hypercholesterolemia
Fadul et al. Reduction of plasma fibrinogen, immunoglobulin G, and immunoglobulin M concentrations by immunoadsorption therapy with tryptophan and phenylalanine adsorbents
Tagawa et al. Ability to Remove Immunoglobulins and Antiganglioside Antibodies by Double Filtration Plasmapheresis in Guillain‐Barré Syndrome: Is It Equivalent to Plasma Exchange?
EP2288384B1 (fr) Traitement de la thromboangéite oblitérante par élimination d'auto-anticorps
JP2010530360A (ja) 全身性エリテマトーデスを治療するペプチドおよび全身性エリテマトーデスの治療方法
RU2178309C2 (ru) Антитимоцитарный глобулин для внутривенного введения и способ его получения
Splendiani et al. Myasthenia gravis (MG) treatment with immunoadsorbent columns
Yamamoto et al. Selective Removal of Anti‐Acetylcholine Receptor Antibodies and IgG In Vitro with an Immunoadsorbent Containing Immobilized Sulfathiazole
Kannabhiran et al. Transplanting against histocompatibility barriers
Kojima Selective Removal of Plasma Components by High‐Performance Immunoaffinity Chromatography
RU2139100C1 (ru) Способ лечения аллергических заболеваний

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20161115